Cerenome signs in-network deal with Blue Cross Blue Shield of Michigan for CNSide test - CNSY News | RalliesCerenome signs in-network deal with Blue Cross Blue Shield of Michigan for CNSide test
C
CNSY• In-network agreement with Blue Cross Blue Shield of Michigan
- Cerenome signed an in-network provider agreement with Blue Cross Blue Shield of Michigan for its CNSide CSF tumor cell enumeration assay.
- The contract took effect Sept. 1, 2026; BCBSM serves about 5 million commercial and Medicare Advantage members.
- The agreement lifts CNSide contracted reimbursement coverage to about 158 million commercial and Medicare Advantage covered lives.
CLVT
•
